STOCK TITAN
  1. Home
  2. News
  3. ESPR

Esperion Therapeutics, Inc. - ESPR STOCK NEWS

Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.

Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.

In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.

Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.

The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.

News

Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Esperion (NASDAQ: ESPR) is participating in the 42nd Annual J.P. Morgan Healthcare Conference. President and CEO Sheldon Koenig will deliver a corporate presentation on January 10, 2024, at 2:15 PM PT. Esperion focuses on discovering, developing, and commercializing innovative medicines for cardiovascular and cardiometabolic diseases. The company aims to improve outcomes for patients with high cholesterol, providing the next steps to help get patients to their LDL-cholesterol level goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.93%
Tags
conferences
-
News

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

Rhea-AI Summary
Esperion (NASDAQ: ESPR) receives FDA approval for updated label indications for NEXLETOL and NEXLIZET, removing the maximally tolerated statin requirement and limitation of use for primary hyperlipidemia. The approval reinforces the proven efficacy and safety of these treatments. The label updates do not impact the pending approvals for cardiovascular risk reduction indications. The PDUFA date for these approvals is March 31, 2024, and anticipated approval in Europe is in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.57%
Tags
none
-
News

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

Rhea-AI Summary
Esperion (NASDAQ: ESPR) announced results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. The analysis highlighted the potential of bempedoic acid to reduce vascular inflammation, especially in statin-intolerant patients. Results showed a 21.6% reduction in the inflammatory marker hsCRP in patients taking bempedoic acid. Dr. Paul Ridker presented the analysis, emphasizing the importance of inflammation inhibition alongside cholesterol reduction in improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
News

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Rhea-AI Summary
ESPR: Esperion to Participate in TRANSFORM Trial for Heart Disease Evaluation and Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary
ESPR: Esperion Grants 141,800 RSUs to New Employees under 2017 Inducement Equity Incentive Plan. The RSUs will vest over time, subject to continued employment. Esperion is a pharmaceutical company focused on developing innovative medicines for cardiovascular and cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
none
-
News

Esperion Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Esperion (NASDAQ: ESPR) reported Q3 U.S. net product revenue growth of 45% Y/Y to $20.3 million and total revenue growth of 79% Y/Y to $34.0 million. Retail prescription equivalents grew 33% Y/Y and 8% Q/Q. The company received FDA acceptance of the application for expanded CV risk reduction indications with a PDUFA date of March 31. The EMA approval of expanded labels is on track and anticipated in 1H 2024. The company also presented two new CLEAR Outcomes analyses at the European Society of Cardiology, further differentiating NEXLETOL and NEXLIZET from existing LDL-C lowering therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.29%
Tags
earnings
News

Esperion to Participate in Jefferies London Healthcare Conference

Rhea-AI Summary
Esperion (NASDAQ: ESPR) will participate in the Jefferies London Healthcare Conference. Sheldon Koenig, CEO, will have a fireside chat on Nov. 14 at 3:00 AM ET. The management team will also host investor meetings. A live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Esperion to Report Third Quarter 2023 Financial Results on November 7

Rhea-AI Summary
Esperion to report Q3 2023 financial results and host webcast on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences earnings
-
News

American College of Cardiology Program to Increase Cholesterol Screenings

Rhea-AI Summary
The American College of Cardiology, in collaboration with Amgen and Esperion, is launching a quality improvement campaign to increase LDL screening and treatment for cardiovascular disease. The program aims to reach 30,000 primary care providers and cardiologists and will be guided by an independent physician steering committee. The program will assess current levels of LDL screening, test education messages, and observe changes in screening and treatment over a 12-month intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
News

Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary
Esperion announces participation in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
conferences

FAQ

What is the current stock price of Esperion Therapeutics (ESPR)?

The current stock price of Esperion Therapeutics (ESPR) is $2.52 as of November 22, 2024.

What is the market cap of Esperion Therapeutics (ESPR)?

The market cap of Esperion Therapeutics (ESPR) is approximately 476.5M.

What is Esperion Therapeutics, Inc.?

Esperion Therapeutics, Inc. is a pharmaceutical company specializing in developing first-in-class, oral therapies that lower low-density lipoprotein cholesterol (LDL-C).

What products does Esperion offer?

Esperion offers NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to lower elevated LDL-C levels.

What recent achievements has Esperion made?

Esperion recently received broad new label expansions for NEXLETOL and NEXLIZET, covering cardiovascular risk reduction and expanded LDL-C lowering for both primary and secondary prevention patients.

What is ETC-1002?

ETC-1002 is Esperion's lead product candidate, an inhibitor of ATP citrate lyase, an enzyme involved in cholesterol biosynthesis.

What is the significance of the CLEAR Outcomes trial?

The CLEAR Outcomes trial demonstrated the efficacy and safety of bempedoic acid, a key component in NEXLETOL and NEXLIZET, in reducing cardiovascular events in high-risk patients.

Who can benefit from Esperion's medications?

Over 70 million patients, including those with elevated LDL-C levels and those at high risk of cardiovascular events, can benefit from Esperion's medications.

What partnerships does Esperion have?

Esperion has partnered with companies like Otsuka to develop and commercialize bempedoic acid in various regions, including Japan.

What are the common side effects of NEXLETOL and NEXLIZET?

Common side effects include upper respiratory tract infection, muscle spasms, hyperuricemia, and back pain, among others.

How does Esperion support its patients?

Esperion enhances patient support programs and works with payers to improve access to its medications.

What are Esperion's future plans?

Esperion plans to continue clinical development, expand into new markets, and address unmet medical needs in cardiovascular care.

Stock ESPR logo
Esperion Therapeutics, Inc.

Nasdaq:ESPR

ESPR Rankings

#3162 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Stock Data

476.49M
196.07M
0.5%
66.33%
17.05%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR